Brokerages Anticipate Zimmer Biomet Holdings Inc (ZBH) Will Post Earnings of $2.10 Per Share

Equities analysts expect that Zimmer Biomet Holdings Inc (NYSE:ZBH) will report $2.10 earnings per share for the current quarter, according to Zacks. Eleven analysts have made estimates for Zimmer Biomet’s earnings, with the highest EPS estimate coming in at $2.13 and the lowest estimate coming in at $2.07. Zimmer Biomet posted earnings of $2.14 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 1.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, January 30th.

On average, analysts expect that Zimmer Biomet will report full year earnings of $8.03 per share for the current year, with EPS estimates ranging from $8.00 to $8.05. For the next fiscal year, analysts expect that the business will post earnings of $8.19 per share, with EPS estimates ranging from $8.00 to $8.50. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.79 EPS.

ZBH has been the subject of a number of research reports. Zacks Investment Research raised shares of Zimmer Biomet from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. SunTrust Banks reaffirmed a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a report on Monday, October 2nd. Piper Jaffray Companies downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating in a report on Thursday, November 2nd. BMO Capital Markets decreased their price objective on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $136.90.

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Victory Capital Management Inc. raised its stake in shares of Zimmer Biomet by 640.1% during the second quarter. Victory Capital Management Inc. now owns 27,072 shares of the medical equipment provider’s stock valued at $3,476,000 after purchasing an additional 23,414 shares in the last quarter. Geneva Advisors LLC raised its stake in shares of Zimmer Biomet by 2.7% during the second quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after purchasing an additional 55 shares in the last quarter. Andra AP fonden raised its stake in shares of Zimmer Biomet by 15.8% during the second quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after purchasing an additional 2,900 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Zimmer Biomet by 8.3% during the second quarter. Pacer Advisors Inc. now owns 4,598 shares of the medical equipment provider’s stock valued at $590,000 after purchasing an additional 351 shares in the last quarter. Finally, BKS Advisors LLC bought a new stake in shares of Zimmer Biomet during the second quarter valued at about $207,000. Institutional investors and hedge funds own 85.92% of the company’s stock.

Zimmer Biomet (ZBH) opened at $121.75 on Friday. The company has a market cap of $24,650.00, a price-to-earnings ratio of 37.93, a price-to-earnings-growth ratio of 1.90 and a beta of 1.15. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. Zimmer Biomet has a 1-year low of $102.59 and a 1-year high of $133.49.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Zimmer Biomet Holdings Inc (ZBH) Will Post Earnings of $2.10 Per Share” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/29/brokerages-anticipate-zimmer-biomet-holdings-inc-zbh-will-post-earnings-of-2-10-per-share.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit